Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-10T09:35:05.801Z Has data issue: false hasContentIssue false
  • English
  • Français

Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population Level

Published online by Cambridge University Press:  10 March 2009

Reiner M. Leidl
Reiner M. Leidl
Affiliation:
University of Limburg
Get access Rights & Permissions [Opens in a new window]

Abstract

The cost-effectiveness of a medical intervention at the population level may deviate from that reported for evaluations at the patient level. It is important for researchers and decision makers to know about the relevance of externalities, phasing-in effects, treatment effectiveness in the community, capacity issues, and different time perspectives in the evaluation of an intervention.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 3 , Summer 1994 , pp. 467 - 478
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Anderson, R. M., Gupta, S., & May, R. M.Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV 1. Nature, 1991, 350, 356–59.CrossRefGoogle ScholarPubMed
2.Backhouse, M. E., Backhouse, R. J., & Edey, S. A.Economic evaluation bibliography. Health Economics, 1992, 1 (suppl.), 1–236.Google Scholar
3.Banta, H. D., & Bos, M.The relation between quantity and quality with coronary artery bypass graft (CABG) surgery. Health Policy, 1991, 18, 1–10.CrossRefGoogle ScholarPubMed
4.Banta, H. D., Vondeling, H., de Wit, A., & Haan, G.Economic appraisal of laser applications in medicine. Lasers in Medical Science, 1990, 5, 253–69.CrossRefGoogle Scholar
5.Birch, S., & Gafni, A.Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? Journal of Health Economics, 1992, 11, 279–96.CrossRefGoogle ScholarPubMed
6.Culyer, A. J.The nature of the commodity ‘health care’ and its efficient allocation. Oxford Economic Papers, 1971, 23, 189–211.CrossRefGoogle Scholar
7.Detsky, A. S.Guidelines for economic analysis of pharmaceutical products: A draft document of Ontario and Canada. Pharmaco Economics, 1993, 2, 354–61.CrossRefGoogle Scholar
8.Droitcour, J., Silberman, G., & Chelmisky, E.Cross-design synthesis. International journal of Technology Assessment in Health Care, 1993, 9, 440–49.CrossRefGoogle Scholar
9.Drummond, M., Brandt, A., Luce, B., & Rovira, J.Standardizing methodologies for economic evaluation in health care: Practice, problems and potential. International Journal of Technology Assessment in Health Care, 1993, 9, 26–35.CrossRefGoogle ScholarPubMed
10.Drummond, M. F., & Davies, L.Economic analysis alongside clinical trials: Revisiting the methodological issues. International Journal of Technology Assessment in Health Care, 1991, 7, 561–73.CrossRefGoogle ScholarPubMed
11.Gafni, A., & Birch, S.Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal, 1993, 148, 913–29.Google ScholarPubMed
12.Garber, A. M.Competing risks and the cost-effectiveness of health interventions (1989 Annual Meeting Program and Abstracts). Medical Decision Making, 1989, 9, 319.Google Scholar
13.Gerard, K., & Mooney, G.QALY league tables: Handle with care. Health Economics, 1993, 2, 59–64.CrossRefGoogle ScholarPubMed
14.Haan, G.Effects and costs of in-vitro fertilization: Again, let’s be honest. International Journal of Technology Assessment in Health Care, 1991, 7, 585–93.CrossRefGoogle ScholarPubMed
15.Hannan, E. L., O’Donnell, J. F., Kilburn, H., et al. Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals. Journal of the American Medical Association, 1989, 262, 503–10.CrossRefGoogle ScholarPubMed
16.Henry, D.Economic analysis as an aid to subsidisation decisions: The development of Australian guidelines for Pharmaceuticals. Pharmaco Economics, 1992, 1, 54–67.CrossRefGoogle ScholarPubMed
17.Javitt, J. C., Canner, J. K., Frank, R., et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology, 1990, 97, 483–95.CrossRefGoogle ScholarPubMed
18.Javitt, J. C., Lloyd, P. A., Bassi, L. J., et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. Ophthalmology, 1991, 98, 1565–74.Google ScholarPubMed
19.Labelle, R. J., & Hurley, J. E.Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities. Journal of Health Economics, 1992, 11, 259–77.CrossRefGoogle ScholarPubMed
20.Laupacis, A., Feeney, D., Detsky, A., et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992, 146, 473–81.Google ScholarPubMed
21.Leidl, R.A survey of the economic evaluation of early drug intervention in HIV infection. Working towards a population-based approach. In Kaplan, E. H. & Brandeau, M. L. (eds.), Modeling the AIDS epidemic: planning, policy, and prediction. New York: Raven Press, 1994, 253–71.Google Scholar
22.Morgenstern, W., Chigan, E., Prokhorskas, R., et al. (eds.). Models of noncommunicable diseases. Health status and health service requirements. Berlin: Springer, 1992.Google Scholar
23.Paltiel, A. D., & Kaplan, E. H.Modeling Zidovudine therapy: A cost-effectiveness analysis. Journal of the Acquired Immune Deficiency Syndrome, 1991, 4, 795–804.Google ScholarPubMed
24.Postma, M. J., Leidl, R., Downs, A. M., et al. Economic impact of the AIDS epidemic in EC countries: Towards multinational scenarios on hospital care and costs AIDS, 1993, 7, 541–53.CrossRefGoogle ScholarPubMed
25.Rosendal, H., Vondeling, H., & Banta, H. D.Diffusion of medical lasers in the Netherlands. In Spinelli, P., Dal Fante, M., & Marchesini, R. (eds.), Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier, 1992, 122–26.Google Scholar
26.Schulman, K. A., Lynn, L. A., Glick, H. A., & Eisenberg, J. M.Cost-effectiveness of low-dose Zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Annals of Internal Medicine, 1991, 14, 798–802.CrossRefGoogle Scholar
27.Tugwell, P., Bennett, K. J., Sackett, D. L., & Haynes, R. B.The measurement iterative loop: A framework for the critical appraisal of need, benefits and costs of health interventions. Journal of Chronic Diseases, 1985, 38, 339–51.CrossRefGoogle Scholar
28.van Hout, B., Bonsel, G., Habbema, D., & van der Maas, P.Heart transplantation in the Netherlands; Cost, effects and scenarios. Journal of Health Economics, 1993, 12, 73–93.CrossRefGoogle ScholarPubMed
29.Vrieze, O. J., Kuipers, J., & Boas, G.Scenario analysis in public health and competing risks. Statistica Applicata, 1990, 2, 371–93.Google Scholar
30.Weinstein, M. C., Coxon, P. G., Williams, L. W., et al. Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model. American Journal of Public Health, 1987, 77, 1417–26.CrossRefGoogle ScholarPubMed
31.Yashin, A. I., Manton, K. G., & Vaupel, J. W.Mortality and aging in a heterogeneous population: A stochastic process model with observed and unobserved variables. Theoretical Population Biology, 1985, 27, 154–75.CrossRefGoogle Scholar